ArticleArchives of medical science : AMS2025
Melatonin enhances the viability of random-pattern skin flaps by activating the NRF2 pathway.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Physiological relevance of autocrine melatonin signaling in pineal and extrapineal sites: a systematic review.Function (Oxford, England) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Random skin flap transplantation has been widely used in reconstructive and plastic surgery. As a well-known antioxidant, melatonin has the functions of eliminating reactive oxygen species (ROS), promoting angiogenesis, and protecting against ischemia-reperfusion injury (IRI). We explored the effects of melatonin on random skin flap survival and the potential molecular mechanisms. Material and methods: A total of 72 rats were randomly assigned to the control group, the melatonin (MEL) group, and MEL + ML385 groups. After construction of the random skin flap model, these groups were treated with physiological saline, melatonin, and melatonin + ML385, respectively. The general conditions of random skin flaps were observed daily after the procedure. Laser doppler blood flow (LDBF) imaging was used to evaluate the subcutaneous vascular network. On postoperative day 7, the animals were euthanized to obtain random skin flap specimens. Hematoxylin-eosin (HE) staining was used to evaluate the vessel density. Immunohistochemistry, immunofluorescence staining, and western blotting were used to evaluate the expression of proteins involved in angiogenesis, oxidative stress, and inflammation. Results: Compared to the control group, the MEL group exhibited lower tissue water content, a more abundant vascular network, and higher vascular density, thereby enhancing the survival of random skin flaps. Additionally, the MEL group showed increased expression of angiogenesis-related proteins, enhanced expression of antioxidant proteins, and decreased expression of inflammatory factors. Furthermore, ML385, a specific nuclear factor erythroid-2-related factor 2 (NRF2) inhibitor, reversed the beneficial effect of melatonin on random skin flaps. Conclusions: The findings of our present study demonstrated that melatonin promotes angiogenesis and inhibits oxidative stress and inflammation by activating the NRF2 signaling pathway, thus improving the survival of random skin flaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.